Skip to main content

Cronos Group Inc(CRON-T)
TSX

Today's Change
Real-Time Last Update
Day Low2.80
Day High2.91
Open:2.81
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Cronos Group Reports 2024 Third Quarter Results
GlobeNewswire
Cronos Group Inc. to Hold 2024 Third Quarter Earnings Conference Call on November 12, 2024
GlobeNewswire
Spinachยฎ Is the Number One Cannabis Brand in Canada
GlobeNewswire
Lord Jonesยฎ Live Resin Vapes and Ice Water Hash Pre-Rolls Now Available Across Canada
Baystreet
Stocks in play: Cronos Group Inc.
GlobeNewswire
Cronos Group Reports 2024 Second Quarter Results
GlobeNewswire
Cronos Group Inc. to Hold 2024 Second Quarter Earnings Conference Call on August 8, 2024
GlobeNewswire
Cronos Group Inc. Announces Results of Reconvened 2024 Annual Meeting of Shareholders
GlobeNewswire
Cronos Group Inc. to Reconvene Virtual 2024 Annual Meeting of Shareholders
GlobeNewswire
Cronos Brand Spinachยฎ Celebrates Summer with New Launches
GlobeNewswire
Cronos Group Inc. Announces Results of 2024 Annual Meeting of Shareholders
GlobeNewswire
Cronos Group Announces Expansion of GrowCo to Fuel Global Growth
GlobeNewswire
Cronos Group Inc. to Speak at Bernstein's 40th Annual Strategic Decisions Conference
GlobeNewswire
Cronos Terminates Sale-Leaseback of Peace Naturals Campus
GlobeNewswire
Cronos Group Reports 2024 First Quarter Results
Baystreet
Stocks in play: Cronos Group Inc.
GlobeNewswire
Cronos Enters United Kingdom Cannabis Market
GlobeNewswire
Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders

Profile

Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.